Extrahepatic, cell-specific delivery of LNPs through competitive inhibition of ApoE-mediated uptake

Abstract

Targeted lipid nanoparticles (LNPs) for extrahepatic drug delivery are limited by apolipoprotein E (ApoE)-mediated hepatic accumulation. We developed NanoPilot, a modular fusion protein platform comprising antibodies and anchors blocking the low density lipoprotein receptor (LDLR) ApoE binding site, to block LNP liver uptake and redirect to target cells. NanoPilot can be applied to preformulated LNPs in 10 minutes with two pipetting steps. In vitro, an anti-CD3{varepsilon} NanoPilot increased T-cell transfection 40-fold and reduced monocyte transfection 10-fold in human peripheral blood mononucleocytes. In immunocompetent mouse models, NanoPilot-coated LNPs achieved 30-40% splenic and hepatic T-cell transfection whilst bulk liver accumulation was reduced 3-fold. An anti-c-Kit NanoPilot was further shown to enhance delivery to a haematopoietic stem cell-like cell line in an in-vitro co-culture assay. NanoPilot establishes a versatile framework for the systemic delivery of genetic therapies through concomitant cell-specific targeting and off-target blocking. Further research will assess potential clinical applications.